Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)



Technology Name
(St. Jude Reference #)
Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
Description Researchers at St. Jude have identified novel small molecules that target RNA dependent RNA polymerase. These 4,5-dihydroxypyrimdines bind to the PA(N) endonuclease active site and act as anti-influenza inhibitors. These broad-spectrum anti-viral, pyrimidinone compounds can be developed to treat and prevent influenza.

In the event of a pandemic, antiviral drugs and non-pharmaceutical means of controlling infections are the first line defense. Currently, there are two antiviral drug options for treating influenza: M2 ion channel blockers, such as amantadines that block endocytosis and fusion of cells or the use of neuraminidase inhibitors such as oseltamivir and zanamivir that block viral release. However, amantadine has become very ineffective as a treatment, and oseltamivir seems to require much higher doses to be effective. Therefore, a novel therapeutic could offer substantial benefit. .
Keywords Influenza, therapeutic, small molecule, inhibitor, RNA
Granted Patents or Published Applications  
Related Scientific References Baughman BM, Jake Slavish P, DuBois RM, Boyd VA, White SW, Webb TR; Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay; ACS Chem Biol. 2012 Mar 16;7(3):526-34
Licensing Opportunities We are currently seeking licensing opportunities for the development of influenza therapeutic based on this technology.
   

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: April 2014